← Back to Search
Large Porous Particles For Pulmonary Drug Delivery.
D. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Benjebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, R. Langer
Published 1997 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation. Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic payload. Inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin particles had this effect for only 4 hours. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles.
This paper references
J. Aerosol Sci
J W Tom (1991)
Biomaterials Proc. Soc. Exp. Med. J. Controlled Release
H Kawaguchi (1961)
J. Pharm. Sci
F Komada (1994)
February REPORTS www.sciencemag.org ⅐ SCIENCE ⅐
Topics in Pharmaceutical Sciences Eds. (Medpharm Scientific
I Gonda (1991)
Crit. Rev. Ther. Drug Carrier Syst
R Niven (1995)
Perez de la Cruz for helpful technical assistance
Adv. Drug Delivery Rev.
F. Welt (1997)
Synthesis of Poly(L-lactic acid-co-L-lysine) Graft Copolymers
J. Hrkach (1995)
F Y Liu (1993)
Remington:the science and practice of pharmacy
A. R. Gennaro (1995)
P Colthorpe (1992)
S Cohen (1991)
Bioavailability was determined as (AUC inhaled / AUC subcutaneous ) ϫ 100, where AUC is area under the curve
Biopharm. Sci. Pharm. Res
D Ganderton (1990)
Ann. N.Y. Acad. Sci
O Einarsson (1995)
Interleukin‐11 in Respiratory Inflammation
O. Einarsson (1995)
Aerosols and the Lung: Clinical and Experimental Aspects
S. Clarke (1984)
PLGA particles were made using the double-and single-emulsification solvent evaporation procedures
D A Edwards
Int. J. Pharm
Le Corre (1994)
The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheal and Aerosol Administration to the Rabbit
P. Colthorpe (2004)
New methods of drug delivery.
R. Langer (1990)
Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung.
Fusao Komada (1994)
Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles.
H. Kawaguchi (1986)
Crit. Rev. Ther. Drug Carrier Syst
I Gonda (1990)
Delivery of biotherapeutics by inhalation aerosol.
R. Niven (1995)
Supported by an NSF CAREER Grant (D.E., J.M.) and NIH grants GM26698 (R.L.) and HD29125 (R.L., J.H.)
J. Heidel (1997)
Microscopy Res. Tech
M B Warheit (1985)
This paper is referenced by
Emerging trends in inhaled drug delivery
A. J. Hickey (2020)
Nano‐in‐Micro Sildenafil Dry Powder Formulations for the Treatment of Pulmonary Arterial Hypertension Disorders: The Synergic Effect of POxylated Polyurea Dendrimers, PLGA, and Cholesterol
Rita B. Restani (2020)
Targeted Drug Delivery to Upper Airways Using a Pulsed Aerosol Bolus and Inhaled Volume Tracking Method
Y. Ostrovski (2019)
Thermosensitive polysaccharide particles for pulmonary drug delivery
T. Sato (2019)
Solvent effects on the controlled dense gas precipitation of model proteins
R. Thiering (2000)
A Guide to Pharmaceutical Particulate Science
A. J. Hickey (2003)
Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules.
C. Lombry (2004)
Respirable Microspheres for Inhalation
M. Sakagami (2005)
Novel sustained release microspheres for pulmonary drug delivery.
R. O. Cook (2005)
Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats.
E. Karathanasis (2006)
First approved inhaled insulin therapy for diabetes mellitus
R. Jani (2007)
Respirable microparticles of aminoglycoside antibiotics for pulmonary administration
C. Parlati (2009)
Microfluidic characterization of sustained solute release from porous supraparticles.
V. Rastogi (2010)
Pulmonary formulations: what remains to be done?
J. Weers (2010)
Nanoparticles for Pulmonary Delivery
A. B. Watts (2011)
Chitosan-interferon-β gene complex powder for inhalation treatment of lung metastasis in mice.
H. Okamoto (2011)
Mechanisms of absorption and elimination of drugs administered by inhalation.
Mariam Ibrahim (2013)
Core–shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants
Libo Wu (2007)
Physical approaches to biomaterial design.
S. Mitragotri (2009)
Hormone delivery: small synthetic molecular mimics.
J. Lopez-Liuchi (1998)
Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery.
L. Cruz (2011)
Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.
D. Cipolla (2014)
Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying.
F. Wan (2016)
The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy
Ninell P Mortensen (2014)
Well-designed microcapsules fabricated using droplet-based microfluidic technique for controlled drug release
Zexia Luo (2017)
Particles with Tunable Porosity and Morphology by Controlling Interfacial Instability in Block Copolymer Emulsions.
K. Ku (2016)
Development of dry salbutamol sulfate powder with high inhalation performance independent of inhalation patterns.
D. Hira (2012)
Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery
T. Shen (2015)
Analysis of cohesion forces between monodisperse microparticles with rough surfaces
A. Baldelli (2016)
Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model
V. Labhasetwar (1999)
Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
C. Bosquillon (2001)
Microparticles for intranasal immunization.
M. Vajdy (2001)See more